Cardiometabolic clinical research was affected by healthcare directives curtailing outpatient and elective procedures, as well as those encouraging people to stay home whenever possible. In response to these protocols, new guidances emerged from FDA, EMA, and ESC to enable clinical trials to adapt under COVID-19 conditions. The experts at Worldwide Clinical Trials outline operational shifts made in response to the pandemic and predict how they impact the future of cardiovascular studies.
Authors:
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
Eteri Tsetskhladze, MD, PhD, FESC, FACC
Vice President, General Medicine Medical Lead, Medical Affairs
